March 14, 2023

Shaanxi Micot Technology CO.,LTD, a private biopharmaceutical company, today announced that the last patient of the initial targeted therapeutic dose cohort has successfully completed study treatment in the US FDA approved Phase II clinical trial. The main objective of the study is to determine the safe and well tolerated dose of MT1002 in patients with acute coronary syndrome (ACS) with non-ST-segment elevation myocardial infarction (NSTEMI) who undergone early percutaneous coronary intervention (PCI). The participating countries are US, Canada, Australia and New Zealand.

MT1002 was safe and well-tolerated in all patients enrolled in the study. None of the patients who received MT1002 experienced serious adverse events, major bleeding events or major adverse cardiovascular events.  All key study objectives have been accomplished on this cohort.

“We are very excited to have achieved this important milestone of our leading novel bispecific polypeptide asset.” stated Dr. Bing Wang, Micot Chairman and CEO. “Micot will continue to advance our drug development to late phase clinical trials to help save patients’ lives.” 

陕西麦科奥特科技有限公司今日宣布: 注射用MT1002经美国FDA批准的国际多中心临床II期研究中，目标治疗剂量组的最后一名患者已成功完成治疗出组。该研究的主要目的是确定MT1002在急性冠脉综合征（ACS）伴非ST段抬高型心肌梗死（NSTEMI）和早期经皮冠状动脉介入治疗（PCI）患者中的安全且耐受性良好的剂量，并验证该药物的初步疗效。参与国是美国、加拿大、澳大利亚和新西兰。

MT1002在所有参加研究的患者中均成功完成PCI手术，且安全且耐受性良好。接受MT1002治疗的患者均未发生严重不良事件、大出血事件或重大心血管不良事件。所有关键药效研究目标均达到预期。

MT1002是全球首创抗凝及抗血小板的双拮抗剂，预计在后续临床使用中可以减少医生使用DTI+GPI两类药物联用的配伍不当问题，降低患者出血风险，并且对患者正常凝血和血小板功能无不良影响。

MT1002中美临床Ⅰ期结果已显示出该药物良好的安全性及具有凝血酶抑制及抗血小板聚集双重作用，该II期数据进一步验证了以上药物设计理念。麦科奥特董事长兼首席执行官王冰博士表示：我们非常高兴在创新双特异性多肽药物领域，我们重点研发项目MT1002能够实现这一重要里程碑。麦科奥特将继续推进我们的药物研发到后期临床试验,以帮助挽救更多患者的生命。